COPD Payer research
Objectives: Payer research to assess unmet needs in COPD, perceptions of current therapeutic approaches, evidence requirements, attractive value propositions and market access considerations
Therapy Area: COPD (mild/moderate/severe)
Client: USA pharma company
Product/Technology: Drug
Scope: 7 countries (UK, US, Can, Aus, Swe, Fra, Ger)
Our Workplan: Developed multi-country discussion guides and recruited and interviewed senior payers and payer advisors
Project Duration: 14 weeks
Outcome: Key output was a 109 slide presentation detailing our findings per market and drawing cross-market inferences. Analysis included a ranking of importance for many of the aspects investigated (type of data required, design of clinical study, choice of primary endpoint and mechanisms of outcome measurement etc.) as well as a prospective evaluation of how needs and expectations would change over the next few years.
Case Studies
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals